Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medical Developments International's enterprise value is A$41.29 Mil.
Medical Developments International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.66 Mil. Therefore, Medical Developments International's EV-to-EBITDA for today is 15.50.
ASX:MVP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.32 Med: 17.74 Max: 177
Current: 15.5
During the past 13 years, the highest EV-to-EBITDA of Medical Developments International was 177.00. The lowest was -29.32. And the median was 17.74.
ASX:MVP's EV-to-EBITDA is ranked worse than 59.16% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs ASX:MVP: 15.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Medical Developments International (ASX:MVP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medical Developments International's PE Ratio (TTM) for today is calculated as:
Medical Developments International's share price for today is A$0.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medical Developments International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medical Developments International's EV-to-EBITDA falls into.
Medical Developments International's current Enterprise Value is A$41.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medical Developments International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International (ASX:MVP) has a EV-to-EBITDA of 15.50 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medical Developments International. This is 13% below median its historical median of 17.74. According to the industry distribution chart, Medical Developments International ranks #439 out of 742 companies in the Drug Manufacturers industry, placing it in the top 59.2%.
Is Medical Developments International's EV-to-EBITDA too high?
Medical Developments International's current EV-to-EBITDA of 15.50 is 13% below median its 10-year median of 17.74. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Medical Developments International's value of 15.50 is 19.4% above this industry median. Based on the distribution chart, Medical Developments International ranks #439 out of 742 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Medical Developments International has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #439 out of 742 companies for EV-to-EBITDA. This places Medical Developments International in the lower half of its industry. The industry median EV-to-EBITDA is 12.98. Medical Developments International's value of 15.50 is 19.4% above this benchmark. While the company's 10-year median is 17.74 vs. the industry median of 12.98, Medical Developments International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current EV-to-EBITDA of 15.50 is 19.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medical Developments International. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current EV-to-EBITDA is 15.50, which is 13% below median its own 10-year median of 17.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.65, compared to a current price of A$0.50 — trading 23.1% below its estimated fair value. The current EV-to-EBITDA is 15.50, which is 13% below median its 10-year median of 17.74 and 19.4% above the Drug Manufacturers industry median of 12.98. Medical Developments International's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current EV-to-EBITDA is 15.50 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.50 is trading 23.1% below its estimated GF Value™ of A$0.65.
GuruFocus considers Medical Developments International to be Modestly Undervalued.
Key valuation signals for ASX:MVP:
EV-to-EBITDA: 15.50 (13% below median its 10-year median of 17.74)
GF Value™: A$0.65 vs. price of A$0.50 (23.1% below fair value)
Industry Position: 19.4% above the Drug Manufacturers median (#439 of 742)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Business Description
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
53GF Score
Get the complete analysis for ASX:MVP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 
